Mebiopharm Co., Ltd.

Mebiopharm Co., Ltd. (メビオファーム株式会社) is a Japanese drug-discovery venture headquartered in Tokyo. The company was established on July 15, 2002, with capital of 10 million yen. Its core business is the development of anticancer drugs and other therapeutics using drug delivery system (DDS) technology, specifically applying liposomal encapsulation and conjugating transferrin to the liposome surface to enable targeted transport of anticancer agents. Mebiopharm also sells human-derived GMP-grade holo-transferrin. The company has pursued partnerships and clinical development internationally. In February 2004 it received a contract from Mochida Pharmaceutical for DDS development and evaluation of M76001, and in September 2004 it established a branch in the United States. In 2010 it formed a partnership with Beijing Taide Pharmaceutical of China and simultaneously carried out a third-party allotment of new shares worth 300 million yen, making Beijing Taide Pharmaceutical its second-largest shareholder. Mebiopharm listed on the TOKYO AIM exchange on July 15, 2011, and moved to the Tokyo Stock Exchange TOKYO PRO Market in July 2012. It was delisted from TOKYO PRO Market on June 7, 2013. Mebiopharm's pipeline has included MBP-426, a transferrin-targeted liposomal cisplatin derivative that entered international clinical trials, and MBP-Y003, a liposomal anticancer agent licensed to Fuan Pharmaceutical (Group) Co., Ltd. of China for development and sales in China for a one-time contract fee of 1 million US dollars. The company has also been involved in siRNA delivery research, including a joint research agreement with Nagoya City University Graduate School of Pharmaceutical Sciences on a drug delivery system for the nucleic acid drug Nek2 siRNA. Mebiopharm has presented at numerous international clinical trials and drug delivery conferences and has been featured in industry publications such as Scrip Intelligence Online.

Mebiopharm Co., Ltd. was established on July 15, 2002, in Tokyo with capital of 10 million yen as a drug-discovery venture. The company focused on applying drug delivery system (DDS) technology, particularly liposomal encapsulation, to develop anticancer drugs. Its approach involves conjugating transferrin to the liposome surface to enable targeted delivery of anticancer agents. In February 2004, Mebiopharm received a contract from Mochida Pharmaceutical for DDS development and evaluation of M76001. In September 2004, it established a branch in the United States. In 2010, Mebiopharm formed a partnership with Beijing Taide Pharmaceutical of China and simultaneously conducted a third-party allotment of new shares worth 300 million yen, making Beijing Taide Pharmaceutical the second-largest shareholder. On July 15, 2011, Mebiopharm listed on the TOKYO AIM exchange. However, the IPO was troubled: the provisional price range was set at 1,200–1,600 yen, but selling pressure persisted from the first day, and the first trade at 286 yen occurred only on the fifth day, July 22, 2011. Just before listing, on July 7, 2011, the company canceled its originally planned public offering. In July 2012, Mebiopharm moved from TOKYO AIM to the Tokyo Stock Exchange TOKYO PRO Market. On June 7, 2013, it was delisted from TOKYO PRO Market. Despite the delisting, the company continued its research and development activities. In May 2015, it licensed MBP-Y003, a liposomal anticancer agent, to Fuan Pharmaceutical (Group) Co., Ltd. of China for development and sales in China for a one-time contract fee of 1 million US dollars. In October 2015, it entered a license agreement with R-Tech Ueno for a new anticancer agent. In May 2016, it announced a joint research agreement with Nagoya City University Graduate School of Pharmaceutical Sciences on a drug delivery system for the nucleic acid drug Nek2 siRNA, and received a three-year AMED grant for an ovarian cancer project with the University of Tokyo. Mebiopharm has also been active in international conferences and industry publications. It presented at events such as the 4th Annual Partnerships in Clinical Trials, Clinical Trials Asia, and the 2nd DDS Drug Development Focus Group. It was featured in Scrip Intelligence Online in May 2013 regarding venturing into the Japanese investment market. The company also sells human-derived GMP-grade holo-transferrin.

• Founded with capital of 10 million yen

• Received contract from Mochida Pharmaceutical for DDS development and evaluation of M76001

• Established US branch

• Partnership with Beijing Taide Pharmaceutical; 300 million yen third-party allotment

• Listed on TOKYO AIM

• First trade at 286 yen on the fifth day after listing

• Moved from TOKYO AIM to Tokyo Stock Exchange TOKYO PRO Market

• Delisted from Tokyo Stock Exchange TOKYO PRO Market

• MBP-Y003 licensed to Fuan Pharmaceutical (Group) Co., Ltd. for China development and sales for USD 1 million

• License agreement with R-Tech Ueno for new anticancer agent

• Joint research agreement with Nagoya City University on DDS for Nek2 siRNA; AMED 3-year grant for ovarian cancer project with University of Tokyo

Drug discovery venture specializing in DDS technology for targeted cancer therapy.

• MBP-426

  Transferrin-targeted liposomal cisplatin derivative; entered international clinical trials

• MBP-Y003

  Liposomal anticancer agent licensed to Fuan Pharmaceutical for China

• Human-derived GMP-grade holo-transferrin

  Sold as a research reagent

1. 1Mebiopharm official websitemebiopharm.com
2. 2メビオファーム - Wikipediaja.wikipedia.org
3. 3Mebiopharm - Wikidatawikidata.org